Tahlia Meola

Research Interests

Clinical Trials Pharmaceutical Sciences

Dr Tahlia Meola

Lecturer B

School of Pharmacy and Biomedical Sciences

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Tahlia Meola is an early career pharmaceutical scientist within the Clinical Pharmacology and Therapeutics Research Group at the University of South Australia. Her doctoral work focussed on developing innovative pharmaceutical formulations to overcome the challenges associated with the oral delivery of drugs, specifically to improve drug absorption to enable easier dosing regimens and improve patient compliance. Tahlia’s current research partners with pharmaceutical industry to explore rationale dosing regimens to optimise medicine use. Tahlia has extensive experience in early phase clinical trial conduct in accordance with regulatory standards, managing all aspects from study design to clinical trial reporting.

Date Position Institution name
2023 - ongoing Research Fellow University of South Australia

Date Institution name Country Title
2017 - 2022 University of South Australia Australia Doctor of Philosophy
2016 - 2017 University of South Australia Australia Bachelor of Biomedical Research (Honours)
2013 - 2015 University of South Australia Australia Bachelor of Pharmaceutical Science

Year Citation
2026 Meola, T. R., La Fontaine, K., Condon, J., Wabnitz, P., Fornasini, G., Evans, A. M., & Reuter, S. E. (2026). Alternative Dosing Strategies to Enhance the Absorption of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) in Healthy Adult Males. Clinical Drug Investigation, 46(5), 1-10.
DOI
2026 Biris, E., Selby, P. R., Meola, T. R., & Reuter, S. E. (2026). Evaluation of Current and Novel Dosing Strategies for Anti-Thymocyte Globulin in Adult Allogeneic Hematopoietic Stem Cell Transplantation.. CPT Pharmacometrics Syst Pharmacol, 15(5), e70176.
DOI
2025 Meola, T. R., Ludbrook, G., Fornasini, G., Pavlova, O., Jain, S., Evans, A. M., & Reuter, S. E. (2025). Absolute bioavailability and intravenous pharmacokinetics of N-acetyl-D-mannosamine in humans. British Journal of Clinical Pharmacology, online(2), 1-7.
DOI Scopus1 WoS1 Europe PMC1
2024 Meola, T. R., Kamath, S., Elz, A. S., Prestidge, C. A., Wignall, A., & Joyce, P. (2024). Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic. European Journal of Pharmaceutics and Biopharmaceutics, 203, 10 pages.
DOI Scopus5 WoS4 Europe PMC3
2024 Meola, T. R., Elz, A., Wignall, A., Paxton, K., Hunter, A., Ariaee, A., . . . Joyce, P. (2024). Inulin-Lipid Core–Shell Microcapsules Target the Gut Microbiota and Mimic the Pharmaceutical Food Effect for Improved Oral Antipsychotic Delivery. Advanced Functional Materials, 34(40), 12 pages.
DOI Scopus21 WoS19
2024 Boord, M. S., Brown, P., Soriano, J., Meola, T., Dumuid, D., Milte, R., . . . Lim, R. (2024). A Digitally Enabled, Pharmacist service to detecT medicine harms in residential aged care (nursing home) (ADEPT): protocol for a feasibility study. BMJ Open, 14(2), e080148.
DOI Scopus3 WoS1 Europe PMC1
2024 Evans, A. M., Fornasini, G., Meola, T. R., Gahl, W. A., Huizing, M., Polasek, T. M., & Reuter, S. E. (2024). Impact of Food on the Oral Absorption of N-Acetyl-D-Mannosamine in Healthy Men and Women. Clinical Pharmacology in Drug Development, 13(8), 876-883.
DOI Scopus4 WoS4 Europe PMC4
2023 Møller, A., Schultz, H. B., Meola, T. R., Joyce, P., Müllertz, A., & Prestidge, C. A. (2023). The Influence of Blonanserin Supersaturation in Liquid and Silica Stabilised Self-Nanoemulsifying Drug Delivery Systems on In Vitro Solubilisation. Pharmaceutics, 15(1), 14 pages.
DOI Scopus1
2022 Meola, T. R., Bremmell, K. E., Williams, D. B., Schultz, H. B., & Prestidge, C. A. (2022). Bio-enabling strategies to mitigate the pharmaceutical food effect: A mini review. International Journal of Pharmaceutics, 619(121695), 14 pages.
DOI Scopus8 WoS7 Europe PMC5
2022 Oh, J. A., Aakyiir, M., Liu, Y., Qiu, A., Meola, T. R., Forson, P., . . . Ma, J. (2022). Durable cement/cellulose nanofiber composites prepared by a facile approach. Cement and Concrete Composites, 125(104321), 1-13.
DOI Scopus47 WoS44
2021 Meola, T., Abuhelwa, A. Y., Joyce, P., Clifon, P., & Prestidge, C. (2021). A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Delivery and Translational Research, 11(3), 1261-1272.
DOI Scopus36 WoS34 Europe PMC27
2021 Meola, T. R., Joyce, P., Wignall, A., Bremmell, K. E., & Prestidge, C. A. (2021). Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone. International Journal of Pharmaceutics, 608(121098), 10 pages.
DOI Scopus11 WoS11 Europe PMC8
2021 Møller, A., Schultz, H. B., Meola, T. R., Müllertz, A., & Prestidge, C. A. (2021). The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations. European Journal of Pharmaceutical Sciences, 157(article no. 105640), 10 pages.
DOI Scopus10 WoS8 Europe PMC4
2020 Meola, T. R., Schultz, H. B., Peressin, K. F., & Prestidge, C. A. (2020). Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: the effect of supersaturation and silica geometry. European Journal of Pharmaceutical Sciences, 150(105357), 1-10.
DOI Scopus30 WoS27 Europe PMC16
2020 Schultz, H. B., Meola, T. R., Thomas, N., & Prestidge, C. A. (2020). Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. International Journal of Pharmaceutics, 577(119069), 1-12.
DOI Scopus56 WoS53 Europe PMC28
2020 Meola, T. R., Paxton, K., Joyce, P., Schultz, H. B., & Prestidge, C. A. (2020). The effect of drug ionization on lipid-based formulations for the oral delivery of anti-psychotics. Admet and Dmpk, 8(4), 437-451.
DOI Scopus10 WoS10 Europe PMC5
2020 Joyce, P., Meola, T. R., Schultz, H. B., & Prestidge, C. A. (2020). Biomaterials that regulate fat digestion for the treatment of obesity. Trends in Food Science and Technology, 100, 235-245.
DOI Scopus27 WoS23
2020 Joyce, P., Dening, T. J., Meola, T. R., Wignall, A., Ulmefors, H., Kovalainen, M., & Prestidge, C. A. (2020). Contrasting Anti-obesity Effects of Smectite Clays and Mesoporous Silica in Sprague-Dawley Rats. ACS Applied Bio Materials, 3(11), 7779-7788.
DOI Scopus15 WoS14 Europe PMC10
2020 Bremmell, K. E., Briskey, D., Meola, T. R., Mallard, A., Prestidge, C. A., & Rao, A. (2020). A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults. European Journal of Nutrition, 59(6), 2729-2737.
DOI Scopus25 WoS23 Europe PMC17
2019 Joyce, P., Dening, T. J., Meola, T. R., Schultz, H. B., Holm, R., Thomas, N., & Prestidge, C. A. (2019). Solidification to improve the biopharmaceutical performance of SEDDS: opportunities and challenges. Advanced drug delivery reviews, 142, 102-117.
DOI Scopus113 WoS102 Europe PMC71
2019 Joyce, P., Dening, T. J., Meola, T. R., Gustafsson, H., Kovalainen, M., & Prestidge, C. A. (2019). Nanostructured clay particles supplement orlistat action in inhibiting lipid digestion: an in vitro evaluation for the treatment of obesity. European journal of pharmaceutical sciences, 135, 1-11.
DOI Scopus15 WoS14 Europe PMC8
2018 Meola, T. R., Dening, T. J., & Prestidge, C. A. (2018). Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro. European journal of pharmaceutics and biopharmaceutics, 129, 145-153.
DOI Scopus21 WoS17 Europe PMC11

Year Citation
2020 Joyce, P., Schultz, H. B., Meola, T. R., & Prestidge, C. A. (2020). Polymer lipid hybrid (PLH) formulations: A synergistic approach to oral delivery of challenging therapeutics. A synergistic approach to oral delivery of challenging therapeutics. In Delivery of Drugs Volume 2 Expectations and Realities of Multifunctional Drug Delivery Systems (pp. 1-27). Elsevier.
DOI Scopus5
2020 Joyce, P., Schultz, H. B., Meola, T. R., & Prestidge, C. A. (2020). Polymer lipid hybrid (PLH) formulations: a synergistic approach to oral delivery of challenging therapeutics. In R. Shegokar (Ed.), Source details - Title: Delivery of Drugs. Volume 2: Expectations and Realities of Multifunctional Drug Delivery Systems (pp. 1-27). UK: Elsevier.
DOI WoS3

Year Citation
2024 Brungs, D., Hill, J., Aghmesheh, M., Ackland, S. P., Parker, S., Jokela, R. M., . . . Clingan, P. R. (2024). A phase I dose-escalation study of an all-in-one 5-fluorouracil and leucovorin co-formulation administered after failure of standard treatment. In Journal of Clinical Oncology Vol. 42 (pp. 1 page). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS.
DOI

Year Citation
2026 Boord, M. S., Brown, P., Soriano, J., Meola, T. R., Dumuid, D., Milte, R., . . . Lim, R. (2026). A Digitally-Enabled, Pharmacist service to detecT medicine harms in residential aged care (ADEPT): A feasibility study. (Preprint).
DOI
2024 Collins, K., Kamath, S., Meola, T. R., Wignall, A., & Joyce, P. (2024). The Oral Bioavailability of Lurasidone is Impacted by Changes to the Gut Microbiome: Implications for Antipsychotic Therapy.
DOI

Courses I teach

  • PHAR 2024 Clinical Trials for Drug Development (2025)
  • PHAR 2024 Clinical Trials for Drug Development (2024)

Date Role Research Topic Program Degree Type Student Load Student Name
2023 Co-Supervisor Optimising treatment of haematological malignancies through the development of evidence-based dose individualisation strategies Doctor of Philosophy Doctorate Part Time Mr Elias Constantinos Biris

Connect With Me

External Profiles

Other Links